319 related articles for article (PubMed ID: 30019530)
1. Timing of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients.
Asleh R; Briasoulis A; Pereira NL; Boilson BA; Edwards BS; Adigun R; Maltais S; Daly RC; Lerman A; Kushwaha SS
ESC Heart Fail; 2018 Dec; 5(6):1118-1129. PubMed ID: 30019530
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.
Asleh R; Briasoulis A; Kremers WK; Adigun R; Boilson BA; Pereira NL; Edwards BS; Clavell AL; Schirger JA; Rodeheffer RJ; Frantz RP; Joyce LD; Maltais S; Stulak JM; Daly RC; Tilford J; Choi WG; Lerman A; Kushwaha SS
J Am Coll Cardiol; 2018 Feb; 71(6):636-650. PubMed ID: 29420960
[TBL] [Abstract][Full Text] [Related]
3. Hypercholesterolemia after conversion to sirolimus as primary immunosuppression and cardiac allograft vasculopathy in heart transplant recipients.
Asleh R; Briasoulis A; Pereira NL; Edwards BS; Frantz RP; Daly RC; Lerman A; Kushwaha SS
J Heart Lung Transplant; 2018 Nov; 37(11):1372-1380. PubMed ID: 30174165
[TBL] [Abstract][Full Text] [Related]
4. Attenuated-Signal Plaque Progression Predicts Long-Term Mortality After Heart Transplantation: IVUS Assessment of Cardiac Allograft Vasculopathy.
Okada K; Fearon WF; Luikart H; Kitahara H; Otagiri K; Tanaka S; Kimura T; Yock PG; Fitzgerald PJ; Yeung AC; Valantine HA; Khush KK; Honda Y
J Am Coll Cardiol; 2016 Jul; 68(4):382-92. PubMed ID: 27443435
[TBL] [Abstract][Full Text] [Related]
5. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
[TBL] [Abstract][Full Text] [Related]
6. Differential effect of everolimus on progression of early and late cardiac allograft vasculopathy in current clinical practice.
Masetti M; Potena L; Nardozza M; Prestinenzi P; Taglieri N; Saia F; Pece V; Magnani G; Fallani F; Coccolo F; Russo A; Rapezzi C; Grigioni F; Branzi A
Am J Transplant; 2013 May; 13(5):1217-26. PubMed ID: 23621161
[TBL] [Abstract][Full Text] [Related]
7. Cardiac allograft vasculopathy in pediatric heart transplant recipients does early-onset portend a worse prognosis?
Khoury M; Conway J; Gossett JG; Edens E; Soto S; Cantor R; Koehl D; Barnes A; Exil V; Glass L; Kirklin JK; Zuckerman WA
J Heart Lung Transplant; 2022 May; 41(5):578-588. PubMed ID: 35172937
[TBL] [Abstract][Full Text] [Related]
8. Layered Fibrotic Plaques Are the Predominant Component in Cardiac Allograft Vasculopathy: Systematic Findings and Risk Stratification by OCT.
Clemmensen TS; Holm NR; Eiskjær H; Løgstrup BB; Christiansen EH; Dijkstra J; Barkholt TØ; Terkelsen CJ; Maeng M; Poulsen SH
JACC Cardiovasc Imaging; 2017 Jul; 10(7):773-784. PubMed ID: 28330670
[TBL] [Abstract][Full Text] [Related]
9. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
Asimacopoulos EP; Garbern JC; Gauvreau K; Blume ED; Daly KP; Singh TP
Transplantation; 2020 Jan; 104(1):e31-e37. PubMed ID: 31568274
[TBL] [Abstract][Full Text] [Related]
10. Association of Aspirin Treatment With Cardiac Allograft Vasculopathy Progression and Adverse Outcomes After Heart Transplantation.
Asleh R; Briasoulis A; Smith B; Lopez C; Alnsasra H; Pereira NL; Edwards BS; Clavell AL; Stulak JM; Locker C; Kremers WK; Daly RC; Lerman A; Kushwaha SS
J Card Fail; 2021 May; 27(5):542-551. PubMed ID: 33962742
[TBL] [Abstract][Full Text] [Related]
11. Uric acid is an independent predictor of cardiac allograft vasculopathy after heart transplantation.
Asleh R; Prasad M; Briasoulis A; Nardi V; Adigun R; Edwards BS; Pereira NL; Daly RC; Lerman A; Kushwaha SS
J Heart Lung Transplant; 2018 Sep; 37(9):1083-1092. PubMed ID: 29802086
[TBL] [Abstract][Full Text] [Related]
12. Association of Endothelin-1 With Accelerated Cardiac Allograft Vasculopathy and Late Mortality Following Heart Transplantation.
Parikh RV; Khush K; Pargaonkar VS; Luikart H; Grimm D; Yu M; Okada K; Honda Y; Yeung AC; Valantine H; Fearon WF
J Card Fail; 2019 Feb; 25(2):97-104. PubMed ID: 30543947
[TBL] [Abstract][Full Text] [Related]
13. Early aspirin initiation following heart transplantation is associated with reduced risk of allograft vasculopathy during long-term follow-up.
Peled Y; Lavee J; Raichlin E; Katz M; Arad M; Kassif Y; Peled A; Asher E; Elian D; Har-Zahav Y; Shlomo N; Freimark D; Goldenberg I; Klempfner R
Clin Transplant; 2017 Dec; 31(12):. PubMed ID: 28990263
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression.
Raichlin E; Bae JH; Kushwaha SS; Lennon RJ; Prasad A; Rihal CS; Lerman A
J Am Coll Cardiol; 2009 Apr; 53(15):1279-86. PubMed ID: 19358941
[TBL] [Abstract][Full Text] [Related]
15. Prediction model for cardiac allograft vasculopathy: Comparison of three multivariable methods.
Kransdorf EP; Loghmanpour NA; Kanwar MK; Temkit MH; Stehlik J
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181298
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation.
Fearon WF; Okada K; Kobashigawa JA; Kobayashi Y; Luikart H; Sana S; Daun T; Chmura SA; Sinha S; Cohen G; Honda Y; Pham M; Lewis DB; Bernstein D; Yeung AC; Valantine HA; Khush K
J Am Coll Cardiol; 2017 Jun; 69(23):2832-2841. PubMed ID: 28595700
[TBL] [Abstract][Full Text] [Related]
17. Risk Stratification for Cardiac Allograft Vasculopathy in Heart Transplant Recipients - Annual Intravascular Ultrasound Evaluation.
Sato T; Seguchi O; Ishibashi-Ueda H; Yanase M; Okada N; Kuroda K; Hisamatsu E; Sunami H; Watanabe T; Nakajima S; Wada K; Hata H; Fujita T; Fukushima N; Kobayashi J; Nakatani T
Circ J; 2016; 80(2):395-403. PubMed ID: 26701183
[TBL] [Abstract][Full Text] [Related]
18. Relationship between markers of plaque vulnerability in optical coherence tomography and atherosclerotic progression in adult patients with heart transplantation.
Park KH; Sun T; Liu Z; Yang SW; Lennon RJ; Lerman LO; Kushwaha SS; Lerman A
J Heart Lung Transplant; 2017 Feb; 36(2):185-192. PubMed ID: 27461884
[TBL] [Abstract][Full Text] [Related]
19. Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study.
Chih S; Chong AY; Džavík V; So DY; Aleksova N; Wells GA; Bernick J; Overgaard CB; Stadnick E; Mielniczuk LM; Beanlands RSB; Ross HJ
Circ Heart Fail; 2023 Jun; 16(6):e010173. PubMed ID: 37165901
[TBL] [Abstract][Full Text] [Related]
20. Intravascular ultrasound of the proximal left anterior descending artery is sufficient to detect early cardiac allograft vasculopathy.
Floré V; Brown AJ; Pettit SJ; West NEJ; Lewis C; Parameshwar J; Hoole SP
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29194769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
